Pulmonary Langerhans Cell Histiocytosis

Slide 1 · Pulmonary Langerhans

Cell Histiocytosis

Morphology • smoking association • molecular biology • clinical course

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Why this pulmonary disorder deserves recognition

Distinctive histology

Focal Langerhans cell collections, sometimes with eosinophils.

Structural injury

Progressive scarring damages airways and alveoli, producing irregular cysts.

Biologic duality

Smoking responsiveness coexists with evidence of BRAF-driven neoplasia.

Slide 3 · Learning objectives

Recognize the defining cellular population and supportive morphologic features.

Explain the link between cellular lesions, fibrosis, airway damage, and cyst formation.

Interpret the smoking association and BRAF mutations without conflating them.

Differentiate PLCH from adjacent smoking-related interstitial diseases.

Integrate clinicopathologic evidence and the variable natural history.

Slide 4 · Place within diffuse pulmonary diseases

Chronic diffuse lung disease

Broad interstitial/restrictive teaching context

Smoking-related lesions

PLCH discussed beside DIP and RB-ILD

Pulmonary LCH

Unique cellular proliferation and cystic remodeling

Conceptual schematic — editable PowerPoint geometry

Slide 5 · PLCH is a pulmonary phenotype of LCH

Pulmonary presentation

Disease usually discussed in the setting of adult cigarette smoking; Lung injury and cystic remodeling dominate.

Wider LCH spectrum

Histiocytoses are clonal proliferations of dendritic-lineage cells, with several extrapulmonary patterns.

Slide 6 · What the term “histiocytosis” encompasses

Reactive disorders

Some histiocytic proliferations are entirely non-neoplastic.

Langerhans cell histiocytosis

Clonal disorders of Langerhans-type immature dendritic cells.

Aggressive entities

Other histiocytic/dendritic tumors can have high-grade malignant behavior.

Slide 7 · Cell of interest: The Langerhans cell

Langerhans cells

Pale cytoplasm and nuclear folds support cellular recognition.

Eosinophils

May be admixed; They do not define the proliferating cell lineage.

Slide 8 · Why pulmonary LCH is biologically distinctive

Smoking-linked phenotype

Most affected adults are smokers or former smokers, with frequent benefit from smoking cessation.

Driver-mutated subset

Activating BRAF changes demonstrate that a subset belongs in the spectrum of neoplasia.

Slide 9 · Pulmonary disease is rare

Rare, but pattern-forming

The importance is not prevalence: A recognizable combination of Langerhans cells, nodules, cysts, and smoking exposure makes the entity distinctive.

Slide 10 · Strong epidemiologic association with smoking

>90%

Current or former smokers

More than 90% of affected patients as relatively young adult smokers or ex-smokers. This is a case-series description of disease association, not a quantified causal risk among smokers.

Slide 11 · Association does not establish an exclusive cause

A strong smoking association does not imply that every exposed individual develops PLCH.

Smoking status is supportive clinical context, not histologic proof of Langerhans cell proliferation.

The biologic behavior cannot be predicted from smoking exposure alone.

Slide 12 · Smoking cessation is biologically informative

~50%

Improve after cessation

Among affected smokers, about half show improvement after smoking cessation in the Robbins account. Improvement is compatible with an exposure-responsive component, but does not establish a non-neoplastic mechanism in every patient.

Slide 13 · Two interpretations can coexist

Exposure-responsive inflammation

Lesions may improve after removing cigarette smoke, supporting an inflammatory/reactive contribution in some cases.

Clonal neoplasia

Other lesions contain activating BRAF mutations; This molecular finding supports neoplastic proliferation.

Slide 14 · Why the reactive–neoplastic contrast is not a binary test

Clinical regression and neoplastic driver mutations address different aspects of biology.

A lesion with a driver mutation need not progress relentlessly.

A lesion that improves with cessation is not automatically demonstrated to lack a driver mutation.

Avoid inferring molecular status solely from clinical behavior.

Slide 15 · BRAF: A molecular clue to clonality

Activating BRAF variant

A genetic lesion in a signaling kinase

Altered growth signaling

Supports a clonal proliferative process

Neoplastic interpretation

Mutation is evidence against a purely reactive explanation

Conceptual schematic — editable PowerPoint geometry

Slide 16 · Pulmonary-specific BRAF frequency

40%

BRAF-mutated pulmonary LCH

Chapter 13 reports BRAF mutations in approximately 40% of pulmonary lesions. This pulmonary-specific figure must not be replaced by the higher figures reported for LCH overall.

Slide 17 · Genetics of the wider LCH spectrum

RAS signaling

More than 85% of general LCH cases have a driver in components of RAS signaling.

BRAF V600E

A common activating variant in the wider LCH spectrum; General LCH frequency is 55–60%.

MAPK1

Encodes a kinase downstream of BRAF and can be mutated in general LCH.

Slide 18 · Do not transplant general LCH rates into PLCH

General LCH

BRAF alterations in 55–60%, within a broader group of RAS-signaling drivers.

Pulmonary LCH

The same textbook separately states a BRAF mutation frequency of about 40% in pulmonary disease.

Slide 19 · What establishes the basic lung lesion?

Langerhans cells

Pale cytoplasm and nuclear folds support cellular recognition.

Eosinophils

May be admixed; They do not define the proliferating cell lineage.

Slide 20 · Eosinophils accompany—but do not define—the lesion

Defining component

Focal accumulation of Langerhans cells is central to the pulmonary entity.

Variable accompaniment

Eosinophils are often present; Their presence alone cannot establish Langerhans cell identity.

Slide 21 · Cytologic recognition: Nuclear grooves and folds

Nuclear grooves or folds

Morphologic clue in Langerhans cell proliferations; Interpreted with other features.

Slide 22 · Cytoplasm: Pale and sometimes vacuolated

Proliferating Langerhans cells have abundant cytoplasm in the general LCH description.

The cytoplasm may appear vacuolated.

Cell shape and nuclear contours are useful morphologic clues rather than stand-alone molecular evidence.

Slide 23 · Birbeck granules: Ultrastructural signature

Birbeck granule — stylized

Pentalaminar tubule with terminal dilatation

A characteristic ultrastructural feature containing langerin; The “tennis-racket” analogy describes its profile.

Slide 24 · Characteristic immunophenotype in general LCH

CD1a

Typical expression supports Langerhans cell differentiation.

S-100

Frequently expressed; Interpreted within the wider lineage panel.

HLA-DR

Another typical marker’ LCH morphology section.

Slide 25 · Histology, phenotype, and mutation are complementary

Microscopic pattern

Grooved/folded nuclei; Mixed inflammation

Lineage support

CD1a, S-100, HLA-DR; Birbeck granules in general LCH

Biologic support

BRAF driver, when identified, supports neoplasia

Conceptual schematic — editable PowerPoint geometry

Slide 26 · Evolution: Cellular lesions can become fibrotic

Focal LCH collection

Cellular lesion with variable eosinophils

Progressive scarring

Fibrosis remodels the affected lung

Anatomic damage

Airways and adjacent alveoli are lost or distorted

Conceptual schematic — editable PowerPoint geometry

Slide 27 · The airway is a target of destructive remodeling

Cystic space

Airway

Alveolar units

Scarring changes geometry

Fibrosis damages airways and neighboring alveolar tissue; Progressive tissue destruction may leave irregular cystic spaces.

Slide 28 · Alveolar injury contributes to architecture loss

Airway

Alveolar units

Functional lung architecture

An airway and adjacent alveoli form a connected unit; Changes in either compartment can affect lung architecture.

Slide 29 · How irregular cystic spaces arise

Persistent lesion

Focal inflammatory or clonal cell accumulation

Fibrotic injury

Scarring coupled to airway and alveolar damage

Residual space

Irregular pulmonary cystic spaces

Conceptual schematic — editable PowerPoint geometry

Slide 30 · Why “irregular cysts” matters morphologically

Cysts reflect destruction

In PLCH, the source links cystic change to scarring, airway destruction, and alveolar injury. A pulmonary cyst is thus a structural consequence, not simply a diagnostic label.

Slide 31 · Imaging clue: Nodular abnormalities

Nodular abnormalities among the characteristic imaging findings.

Nodules are concordant with a disease containing focal cellular lesions.

Imaging pattern should be integrated with smoking history and tissue findings when available.

Slide 32 · Imaging clue: Cystic abnormalities

The chest imaging phenotype includes cystic abnormalities.

These are structurally intelligible because lesions may scar and destroy airways and adjacent alveoli.

The textbook passage does not establish a cyst-size threshold or zonal distribution criterion.

Slide 33 · Nodules plus cysts: An integrated reading

Cell-rich component

Focal Langerhans cell collections

Tissue response

Fibrosis and destruction of normal lung structure

Imaging phenotype

Nodular and irregular cystic changes

Conceptual schematic — editable PowerPoint geometry

Slide 34 · A single lung can display different lesion states

Cellular emphasis

More conspicuous collections of Langerhans cells with inflammatory admixture.

Scarred emphasis

Progressive parenchymal and airway destruction leaves irregular cystic spaces.

Slide 35 · Why imaging cannot determine lineage alone

Cystic or nodular appearances describe lung architecture, not a specific cell marker.

A Langerhans cell lesion is fundamentally a cellular and lineage diagnosis.

Image interpretation gains specificity from clinical context and, when obtained, pathologic examination.

Slide 36 · DIP: A distinct smoking-related morphology

Primary cell

Pigment-containing smoker’s macrophages fill alveolar airspaces.

Septal response

Mild inflammatory thickening; Fibrosis usually limited.

Clinical setting

Current or former smokers; Often improve with cessation and therapy.

Slide 37 · RB-ILD: Bronchiolar smoker’s macrophages

Localization

Dusty brown macrophages within respiratory bronchioles.

Tissue reaction

Chronic inflammation and mild peribronchiolar fibrosis.

Clinical threshold

RB-ILD implies clinically significant symptoms and functional or imaging findings.

Slide 38 · PLCH versus DIP: Cellular target differs

Pulmonary LCH

Focal Langerhans cell proliferation; Eosinophils may accompany it; Scarring can destroy architecture.

DIP

Predominantly diffuse intraalveolar pigmented macrophages with relatively mild septal thickening.

Slide 39 · PLCH versus RB-ILD: The lesion differs

Pulmonary LCH

Langerhans cell foci that can evolve toward destructive fibrotic cysts.

RB-ILD

Pigmented smoker’s macrophages concentrate in bronchioles with mild peribronchiolar injury.

Slide 40 · Morphologic comparison across smoking-related lung disease

Feature

PLCH

DIP

RB-ILD

Dominant cells

Langerhans cells

Pigmented macrophages

Pigmented macrophages

Primary pattern

Focal collections

Alveolar airspaces

Respiratory bronchioles

Fibrosis

Can destroy airways

Usually mild

Mild peribronchiolar

Distinctive clue

Irregular cysts

Macrophage-rich alveoli

Bronchiolar localization

Slide 41 · The same smoking history can mask different pathology

Exposure ≠ diagnosis

PLCH, DIP, and RB-ILD can all occur in smokers, but the dominant cell type, tissue compartment, and downstream structural effect are different.

Slide 42 · Pulmonary alveolar proteinosis is a useful contrast

PLCH

Focal proliferation of Langerhans cells; Scarring and tissue destruction may produce cysts.

PAP

Surfactant accumulates in alveolar spaces because of impaired GM-CSF-dependent macrophage function.

Slide 43 · General LCH has several clinicopathologic settings

Pulmonary special category

Frequently associated with adult smoking and can regress after cessation.

Unisystem disease

May present in bone or other single-organ locations.

Multisystem disease

Can involve skin, bone, lymph nodes, liver/spleen and marrow.

Slide 44 · Unifocal LCH beyond the lung

The general LCH spectrum includes unifocal lesions, particularly in bone.

Langerhans cell proliferations may be admixed with eosinophils, lymphocytes, plasma cells, or neutrophils.

Some unifocal lesions follow an indolent course and may heal spontaneously.

Slide 45 · Multisystem LCH is clinically different

General multisystem LCH often affects very young children, unlike typical smoking-associated PLCH.

Skin lesions, bone destruction, lymphadenopathy and hepatosplenomegaly may occur.

Bone marrow involvement may cause cytopenias in extensive disease.

Slide 46 · Do not equate pulmonary disease with systemic disease

Pulmonary phenotype

Smoking-associated lesions may occur predominantly in the lung.

Systemic phenotype

Additional tissue involvement belongs to wider LCH clinicopathology and requires separate clinical evidence.

Slide 47 · Age and organ pattern are diagnostic context

Clinical clue

Pulmonary LCH

Multisystem LCH

Typical setting

Relatively young adult smoker

Often early childhood

Dominant emphasis

Lung nodules/cysts

Several organ systems

Biologic issue

Smoking response plus BRAF subset

Clonal systemic disease

Diagnostic caution

Do not infer systemic spread

Do not infer cigarette link

Slide 48 · A reasoned approach to suspected PLCH

Clinical context

Ask about current and previous cigarette use

Imaging pattern

Identify a nodular/cystic abnormality

Tissue confirmation when available

Recognize Langerhans cell morphology and phenotype

Integrate behavior

Consider cessation response and progression

Conceptual schematic — editable PowerPoint geometry

Slide 49 · A pathology report should describe what is seen

Identify the Langerhans-type cell population and characteristic nuclear contours.

Describe eosinophilic and other inflammatory accompaniment, if present.

Record scarring, airway damage, and cystic architectural change where sampled.

Distinguish observed findings from causal interpretation.

Slide 50 · Lineage immunophenotype: Correct evidentiary role

CD1a, S-100 and HLA-DR are typical of LCH Chapter 13.

Marker expression supports cellular identity when correlated with morphology.

A molecular driver and immunophenotype answer different questions: Biology versus lineage.

Slide 51 · BRAF result: What it can—and cannot—show

Positive BRAF driver

Provides evidence that the population has neoplastic molecular features.

Negative or unavailable result

Does not itself establish a purely reactive process or exclude PLCH.

Slide 52 · Prognosis: Favourable is not universal

Most cases

Robbins characterizes the usual prognosis as excellent.

Progressive subset

Some patients develop substantial progression despite the favourable overall description.

Slide 53 · Why a progressive case can become severe

Continued lesion evolution

Scarring in involved regions

Cumulative anatomic loss

Damaged airways and alveolar parenchyma

Severe pulmonary impairment

Advanced disease may require lung transplantation

Conceptual schematic — editable PowerPoint geometry

Slide 54 · Smoking cessation is central to the disease narrative

Exposure removal

Directly addresses the dominant associated exposure.

Clinical response

Approximately half improve in the account.

Continued assessment

Other patients progress; Cessation does not eliminate uncertainty.

Slide 55 · Lung transplantation marks the severe end of PLCH

An uncommon, serious outcome

Although the overall prognosis is often excellent, some patients develop progressive lung damage severe enough to require transplantation.

Slide 56 · Applied case 1: Smoker with nodules and cysts

A relatively young adult smoker has both pulmonary nodular and irregular cystic abnormalities.

Question: Which tissue mechanism unifies the paired radiologic findings,?

Slide 57 · Applied case 1: Mechanistic interpretation

Focal Langerhans cell lesion

Explains cellular/nodular component

Fibrotic progression

Scarring damages the lung

Destructive cyst formation

Airway and alveolar injury form irregular spaces

Conceptual schematic — editable PowerPoint geometry

Slide 58 · Applied case 2: Cells with grooved nuclei

A pulmonary infiltrate contains pale cells with nuclear folds and admixed eosinophils.

Question: Which lineage features from general LCH can support identification of these cells?

Slide 59 · Applied case 2: Morphologic and immunophenotypic answer

Morphology

Abundant pale/vacuolated cytoplasm and grooved or folded nuclei.

Immunophenotype

Typical CD1a, S-100 and HLA-DR expression in general LCH.

Ultrastructure

Characteristic langerin-containing Birbeck granules.

Slide 60 · Applied case 3: Response to smoking cessation

A smoker with pulmonary LCH improves after stopping cigarettes.

Question: Does improvement prove that the original lesion was non-neoplastic? Explain the logic.

Slide 61 · Applied case 3: Response does not settle clonality

Observation

Improvement after cessation is consistent with an exposure-responsive component.

Molecular principle

Some lesions harbor activating BRAF mutations; Clinical improvement is not a molecular assay.

Slide 62 · Four discriminators worth retaining

Question

Finding to prioritize

Who is affected?

Predominantly young adult smokers / ex-smokers

Which cells?

Langerhans cells with possible eosinophils

What injury?

Scarring → airway and alveolar destruction → cysts

What biology?

Cessation-responsive cases plus BRAF-mutated subset

Slide 63 · What is directly established versus inferred

Directly stated

Reasonable teaching synthesis

Focal Langerhans cell collections

A cell-rich focus can explain nodularity

Scarring damages airways/alveoli

Different lesions can show differing activity

Characteristic nodules and cysts

Imaging is supportive, not cell-lineage proof

BRAF mutations in pulmonary subset

Regression does not determine mutation status

Slide 64 · Integrated mechanism of pulmonary LCH

Exposure / driver context

Strong smoking association; BRAF-mutated subset

Cellular lesion

Langerhans cell focus ± eosinophils

Destructive remodeling

Progressive fibrosis and structural damage

Clinical–imaging phenotype

Nodules, irregular cysts, variable course

Conceptual schematic — editable PowerPoint geometry

Slide 65 · Final synthesis: Four essential statements

PLCH is a rare lung disease defined by focal collections of Langerhans cells, often with eosinophils.

Progressive scarring damages airways and alveoli, explaining irregular cystic spaces.

Smoking is strongly associated; Cessation benefits about half of affected smokers.

BRAF mutations support neoplasia in a subset, and a minority experience clinically severe progression.

Slide 66 · Textbook references and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), Chapter 15, “The Lung,” p. 637.

Chapter 13, “Langerhans Cell Histiocytosis,” pp. 571–572, supplies morphology, immunophenotype, general classification, and mutation context.

Smoking-related interstitial disease comparisons are drawn from Chapter 15, p. 637.

Histology, ultrastructure, and imaging shown schematically only; original published diagnostic images were not available for licensed reuse.